T1	Condition 33 37	COPD
T2	Measurement 51 127	American Thoracic Society (ATS)/ European Respiratory Society (ERS) criteria
R1	AND Arg1:T1 Arg2:T2	
T3	Value 160 170	>=40 years
T4	Person 155 159	aged
R2	Has_value Arg1:T4 Arg2:T3	
T5	Person 130 134	Male
T6	Person 138 144	female
*	OR T5 T6
T7	Person 172 179	Females
A1	Optional T7
T8	Condition 195 218	Child Bearing Potential
T9	Negation 191 194	Non
R3	Has_negation Arg1:T8 Arg2:T9	
R4	AND Arg1:T7 Arg2:T8	
T10	Condition 242 265	Child Bearing Potential
T11	Negation 238 241	Non
R5	Has_negation Arg1:T10 Arg2:T11	
T12	Person 283 290	Females
T13	Condition 322 341	functioning ovaries
T14	Condition 376 390	tubal ligation
T15	Condition 394 406	hysterectomy
T17	Condition 427 442	post-menopausal
T16	Person 411 418	females
*	OR T14 T15
T18	Scope 283 406	Females, regardless of their age, with functioning ovaries and who have a current documented tubal ligation or hysterectomy
T19	Scope 411 442	females who are post-menopausal
*	OR T18 T19
T20	Scope 283 442	Females, regardless of their age, with functioning ovaries and who have a current documented tubal ligation or hysterectomy, or females who are post-menopausal
T21	Scope 238 265	Non Child Bearing Potential
R6	Subsumes Arg1:T21 Arg2:T20	
T22	Condition 460 464	COPD
T23	Value 465 480	stage III or IV
T24	Measurement 494 507	GOLD criteria
R7	Has_value Arg1:T24 Arg2:T23	
R8	AND Arg1:T22 Arg2:T24	
T25	Measurement 540 593	Forced Expiratory Volume, measured at 1 second (FEV1)
T26	Value 594 618	<50% of predicted normal
R9	Has_value Arg1:T25 Arg2:T26	
T27	Temporal 520 539	post-bronchodilator
R10	Has_temporal Arg1:T25 Arg2:T27	
T28	Temporal 634 654	post- bronchodilator
T29	Measurement 655 698	FEV1/Inspiratory Vital Capacity (IVC) ratio
T30	Value 699 703	<70%
R11	Has_value Arg1:T29 Arg2:T30	
R12	Has_temporal Arg1:T29 Arg2:T28	
T31	Multiplier 723 733	at least 2
T32	Qualifier 746 752	severe
T33	Qualifier 734 742	moderate
*	OR T33 T32
T34	Condition 753 771	COPD exacerbations
T35	Scope 734 752	moderate or severe
R13	Has_scope Arg1:T34 Arg2:T35	
R14	Has_multiplier Arg1:T34 Arg2:T31	
T36	Drug 815 835	oral corticosteroids
T37	Drug 860 880	oral corticosteroids
T38	Qualifier 839 856	increasing dosage
R15	Has_qualifier Arg1:T37 Arg2:T38	
T39	Drug 888 899	antibiotics
T40	Visit 903 918	hospitalization
*	OR T39 T40 T37 T36
T41	Temporal 920 958	within the 12 months preceding Visit 1
T42	Scope 815 918	oral corticosteroids or increasing dosage of oral corticosteroids and/or antibiotics or hospitalization
R16	Has_scope Arg1:T34 Arg2:T42	
R17	Has_temporal Arg1:T34 Arg2:T41	
T43	Drug 973 988	COPD medication
T44	Temporal 989 1020	within 4 weeks prior to Visit 1
R18	Has_temporal Arg1:T43 Arg2:T44	
T45	Qualifier 966 972	stable
R19	Has_qualifier Arg1:T43 Arg2:T45	
T46	Condition 1099 1106	smokers
T47	Measurement 1114 1129	smoking history
T48	Value 1142 1155	10 pack years
R20	Has_value Arg1:T47 Arg2:T48	
T49	Scope 1157 1321	number of pack years = [number of cigarettes per day / 20] x number of years smoked, e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years
R21	Subsumes Arg1:T48 Arg2:T49	
T52	Temporal 1085 1092	Current
T53	Negation 1096 1098	ex
*	OR T52 T53
T54	Scope 1085 1098	Current or ex
R22	Has_scope Arg1:T46 Arg2:T54	
T55	Observation 1339 1354	managed at home
T56	Visit 1347 1354	at home
T57	Procedure 1339 1346	managed
R23	AND Arg1:T57 Arg2:T56	
R24	multi Arg1:T55 Arg2:T57	
T58	Observation 1356 1367	outpatients
T59	Visit 1356 1367	outpatients
R25	multi Arg1:T58 Arg2:T59	
R26	Subsumes Arg1:T55 Arg2:T58	
T51	Condition 1374 1384	ambulatory
T60	Observation 1389 1417	able to travel to the clinic
T61	Observation 1823 1847	written informed consent
T62	Temporal 1860 1882	prior to participation
R27	Has_temporal Arg1:T61 Arg2:T62	
T50	Observation 1885 1937	Able to comply with the requirements of the protocol
T63	Observation 1945 1971	available for study visits
T64	Visit 1959 1971	study visits
R28	multi Arg1:T63 Arg2:T64	
T65	Temporal 1972 1985	over 52 weeks
R29	Has_temporal Arg1:T63 Arg2:T65	
T66	Drug 1461 1476	COPD medication
T67	Drug 1492 1500	vaccines
T68	Drug 1502 1538	inhaled short-acting beta-2-agonists
T69	Drug 1550 1562	short-acting
T70	Drug 1566 1594	long-acting anticholinergics
T71	Drug 1596 1606	tiotropium
R30	Subsumes Arg1:T70 Arg2:T71	
T72	Drug 1609 1633	systemic beta-2-agonists
T73	Drug 1635 1647	theophylline
T74	Drug 1649 1659	mucolytics
T75	Drug 1661 1673	antioxidants
T76	Drug 1675 1690	beta-1-agonists
T78	Condition 1696 1721	cardiovascular indication
T77	Condition 1724 1748	non-invasive ventilation
R31	AND Arg1:T76 Arg2:T78	
R32	Subsumes Arg1:T77 Arg2:T76	
T79	Multiplier 1750 1759	long term
T80	Procedure 1760 1774	oxygen therapy
T81	Drug 1760 1766	oxygen
R33	multi Arg1:T80 Arg2:T81	
T82	Condition 1788 1801	Cor Pulmonale
A3	Optional T82
*	OR T66 T67 T68 T69 T70 T72 T73 T74 T75
T83	Scope 1461 1673	COPD medication. This includes vaccines, inhaled short-acting beta-2-agonists as needed, short-acting or long-acting anticholinergics (tiotropium), systemic beta-2-agonists, theophylline, mucolytics, antioxidants
A2	Optional T83
A4	Optional T77
A5	Optional T76
A6	Optional T78
R34	Has_multiplier Arg1:T80 Arg2:T79	
A7	Optional T80
*	OR T80 T82 T77
